BioPharma Global in the Media
Sandi Heibel Presents at The University of Vermont
On June 19, 2018, BioPharma Global’s Chief Science Officer, Sandi Heibel, traveled to the University of Vermont to speak in front of [WHOM?]. Her presentation, Regulations of Drugs and Biologics by the Food and Drug Administration, discussed the drug development life cycle, the process of clinical studies, and US FDA policies surrounding designations such as: orphan drug, fast track, breakthrough therapy, regenerative medicine advanced therapy, and accelerated approval.
BioPharma Global Teams Up with Merito Group for March for Babies
Biopharma Global forms joint fundraising team with Merito Group for April’s March for Babies fundraiser. Each year, hundreds of thousands of babies are born prematurely or with birth defects. The money we raise in March for Babies helps fund March of Dimes research and programs towards fostering healthier and stronger babies and mothers.
Clinical Network Services and BioPharma Global Enter Cooperative Partnership
Clinical Network Services (CNS), an international clinical and regulatory service group and BioPharma Global, an Orphan Drug regulatory consultancy, operating as a US-based, not-for-profit corporation, today announced they have signed a cooperative partnership agreement.
Our Chat with Health Professional Radio
Indiana Wesleyan University's Alumni Blog Profiles James LaFlamme
Our CEO, James LaFlamme, has been profiled by Dezaray Barr in the Indiana Wesleyan University Alumni Blog. James graduated from Indiana Wesleyan University in 1988 with a Masters in Management.
While a student at IWU, LaFlamme also held a full-time job as an executive. “I would describe this period of time as intense,” LaFlamme said, “but I met a lot of great people and the learning environment at IWU was outstanding.”
James LaFlamme Introduces BioPharma Global
James LaFlamme introduced BioPharma Global in a new YouTube release answering the following questions: Who is BioPharma Global? What do we do? How do we differentiate ourselves from our competitors? And much more.